Dobutamine During Major Abdominal Surgery

University of Hamburg-Eppendorf100 enrolled

Overview

The PUSH-1 trial is a randomized, single-center pilot trial investigating whether dobutamine administration is feasible in patients having major abdominal surgery.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

100

Conditions

Intraoperative Myocardial Depression

Interventions

DobutamineDRUG

In patient assigned to dobutamine administration, dobutamine (concentration: 5 mg mL-1) will be administered with an infusion rate of 3 µg kg-1 min-1 (ideal body weight).

Routine careOTHER

In patients assigned to routine care, intraoperative hemodynamic management will be in accordance with routine care.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Consenting patients ≥18 years scheduled for elective major abdominal surgery under general anesthesia (expected surgery duration ≥ 120 minutes) * Planned continuous intraarterial blood pressure monitoring using an arterial catheter for clinical indications not related to the trial Exclusion Criteria: * Emergency surgery * Liver or kidney transplantation surgery * Status of post transplantation of kidney, liver, heart, or lung * Pregnancy * Heart rhythms other than sinus rhythm

Locations (1)

University Medical Center Hamburg-Eppendorf

Hamburg, Free and Hanseatic City of Hamburg, Germany

Outcomes

Primary Outcomes

Feasibility of dobutamine administration

The primary outcome "feasibility of dobutamine administration" is defined as dobutamine administration during \>70% of surgery duration in \>80% of all patients.